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Abstract
Background: Recent evidence suggests that endogenous arginase activity potentiates airway
responsiveness to methacholine by attenuation of agonist-induced nitric oxide (NO) production,
presumably by competition with epithelial constitutive NO synthase for the common substrate, L-
arginine. Using guinea pig tracheal open-ring preparations, we now investigated the involvement of
arginase in the modulation of neuronal nitric oxide synthase (nNOS)-mediated relaxation induced
by inhibitory nonadrenergic noncholinergic (iNANC) nerve stimulation.
Methods: Electrical field stimulation (EFS; 150 mA, 4 ms, 4 s, 0.5 – 16 Hz)-induced relaxation was
measured in tracheal preparations precontracted to 30% with histamine, in the presence of 1 µM
atropine and 3 µM indomethacin. The contribution of NO to the EFS-induced relaxation was
assessed by the nonselective NOS inhibitor L-NNA (0.1 mM), while the involvement of arginase
activity in the regulation of EFS-induced NO production and relaxation was investigated by the
effect of the specific arginase inhibitor nor-NOHA (10 µM). Furthermore, the role of substrate
availability to nNOS in EFS-induced relaxation was measured in the presence of various
concentrations of exogenous L-arginine.
Results: EFS induced a frequency-dependent relaxation, ranging from 6.6 ± 0.8% at 0.5 Hz to 74.6
± 1.2% at 16 Hz, which was inhibited with the NOS inhibitor L-NNA by 78.0 ± 10.5% at 0.5 Hz to
26.7 ± 7.7% at 8 Hz (P < 0.01 all). In contrast, the arginase inhibitor nor-NOHA increased EFS-
induced relaxation by 3.3 ± 1.2-fold at 0.5 Hz to 1.2 ± 0.1-fold at 4 Hz (P < 0.05 all), which was
reversed by L-NNA to the level of control airways in the presence of L-NNA (P < 0.01 all). Similar
to nor-NOHA, exogenous L-arginine increased EFS-induced airway relaxation (P < 0.05 all).
Conclusion: The results indicate that endogenous arginase activity attenuates iNANC nerve-
mediated airway relaxation by inhibition of NO generation, presumably by limiting L-arginine
availability to nNOS.
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Background
The inhibitory nonadrenergic noncholinergic (iNANC)
nervous system is the most effective bronchodilating neu-
ral pathway of the airways. Inhibition of nitric oxide syn-
thase (NOS) markedly reduces the iNANC relaxation of
both guinea pigs [1-3] and human airways [4,5], indicat-
ing that nitric oxide (NO) is a major neurotransmitter of
the iNANC system. In addition, vasoactive intestinal
polypeptide (VIP) has been implicated in iNANC relaxa-
tion [6,7], and colocalization of NOS and VIP has been
demonstrated both in guinea pig [8] and in human airway
nerves [9].
NO is generated by a family of NOS isoforms that utilize
the semi-essential amino acid L-arginine, oxygen and
NADPH as substrates to produce NO and L-citrulline [10].
Three isoforms of NOS have been identified: neuronal
NOS (nNOS), endothelial NOS (eNOS) and inducible
NOS (iNOS). In the airways, the constitutive NOS (cNOS)
isoforms are mainly expressed in the iNANC neurons
(nNOS), the endothelium (eNOS) and the epithelium
(nNOS and eNOS), whereas iNOS, which is induced by
proinflammatory cytokines during airway inflammation,
is mainly expressed in macrophages and epithelial cells
[11].
Another L-arginine metabolizing enzyme is arginase,
which hydrolyzes L-arginine to L-ornithine and urea. Argi-
nase is classically considered to be an enzyme of the urea
cycle in the liver, but also occurs in extrahepatic tissues,
including the lung [12,13]. Two distinct isoforms of argi-
nase have been identified in mammals: arginase I, a
cytosolic enzyme, mainly expressed in the liver, and argi-
nase II, a mitochondrial enzyme, which is mainly
expressed in extrahepatic tissues [13]. Extrahepatic argin-
ase has been implicated in the regulation of NO synthesis
by limiting the availability of intracellular L-arginine for
NOS [12-15]. In addition, arginase might be involved in
cell growth and tissue repair via the production of L-orni-
thine, a precursor of polyamines and proline [13]. Both
arginase isoforms are constitutively expressed in the air-
ways, particularly in the bronchial epithelium and in
fibroblasts from peribronchial connective tissue [12].
Using a perfused guinea pig tracheal tube preparation, we
have previously demonstrated that endogenous arginase
activity is functionally involved in the regulation of airway
smooth muscle tone [16]. Endogenous arginase potenti-
ates methacholine-induced airway constriction by dimin-
ishing agonist-induced NO production, by competition
with epithelial cNOS for the common substrate, L-
arginine [16]. Previous studies had demonstrated that L-
arginine availability is indeed a limiting factor for agonist-
induced NO-production and airway relaxation [17].
A role for arginase in the iNANC system has been found
in internal anal sphincter [18] and penile corpus caverno-
sum [19,20]. Thus, arginase inhibition increased electrical
field stimulation (EFS)-induced relaxation of these prepa-
rations, indicating that endogenous arginase activity
attenuates nNOS-mediated NANC relaxation.
The role of endogenous arginase in the regulation of
iNANC-derived NO generation in the airways has not yet
been investigated. In the present study, we demonstrated
that endogenous arginase activity and L-arginine availa-
bility are importantly involved in the modulation of
iNANC nerve-mediated NO-production and relaxation of
guinea pig tracheal smooth muscle.
Methods
Animals
Male specific pathogen free HsdPoc:Dunkin Hartley
guinea pigs (Harlan Heathfield, UK), weighing 500 – 800
g, were used in this study. The animals were group-housed
in individual cages in climate-controlled animal quarters
and given water and food ad libitum, while a 12-h on/12-
h off light cycle was maintained.
All protocols described in this study were approved by the
University of Groningen Committee for Animal
Experimentation.
Tissue preparation
The guinea pigs were sacrificed by a sharp blow on the
head. After exsanguination, the trachea was removed from
the larynx to the bronchi and rapidly placed in a Krebs-
Henseleit (KH) buffer solution of 37°C, gassed with 95%
O2 and 5% CO2. The composition of the KH-solution in
mM was: NaCl 117.50; KCl 5.60; MgSO4 1.18; CaCl2 2.50;
NaH2PO4 1.28; NaHCO3 25.0 and D-glucose 5.50; pH
7.4. The trachea was prepared free of serosal connective
tissue. Twelve single proximal tracheal open-ring prepara-
tions were mounted for isotonic recording (0.3 g preload)
between two parallel platinum point-electrodes in water-
jacketed (37°C) organ baths containing 20.0 ml of gassed
KH-solution and indomethacin (3 µM), which remained
present during the whole experiment to eliminate any
influence of prostanoids.
Electrical field stimulation-induced relaxation 
experiments
After a 30 min equilibration period, tracheal preparations
were relaxed with isoprenaline (0.1 µM) to establish basal
tone. After a washout period of 30 min with three washes
with fresh KH solution, maximal contraction of the tra-
cheal preparations to histamine was determined with
cumulative additions of the agonist (0.1, 1, 10 and 100
µM). After washout (30 min), the tracheal preparations
were precontracted with histamine to 30% of the maximalRespiratory Research 2005, 6:23 http://respiratory-research.com/content/6/1/23
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histamine-induced tone in the presence of atropine (1
µM) to prevent EFS-induced cholinergic airway contrac-
tion. On the plateau, biphasic EFS (150 mA, 4 ms, 4 s, 0.5
– 16 Hz) was applied and frequency response curves (0.5
– 16 Hz in doubling steps) were recorded. Per prepara-
tion, one frequency response curve was performed. When
used, the nonselective NOS inhibitor Nω -nitro-L-arginine
(L-NNA; 100 µM), the specific arginase inhibitor Nω -
hydroxy-nor-L-arginine (nor-NOHA; 10 µM), a combina-
tion of both inhibitors, or L-arginine (0.3, 1.0 or 5.0 mM)
were applied 30 min prior to histamine-addition. In line
with previous observations [21], neither the NOS inhibi-
tor, nor the arginase inhibitor and L-arginine affected ago-
nist-induced tone in the open-ring preparations. All
measurements were performed in triplicate. After the final
EFS-induced relaxation, followed by washout, isoprena-
line (10 µM) was added to establish basal tone.
Data analysis
All individual relaxations elicited by EFS were estimated
as peak height of the EFS-induced response, and were
expressed as a percentage of maximal relaxation as estab-
lished in the presence of isoprenaline. The contribution of
NO to the EFS-induced relaxation was determined by the
effect of the NOS inhibitor L-NNA. Similarly, the role of
arginase activity in the modulation of EFS-induced airway
relaxation was determined by the effect of the arginase
inhibitor nor-NOHA. The role of substrate availability in
EFS-induced airway relaxation was assessed by measuring
the responses in the presence of various concentrations of
exogenous L-arginine.
All data are expressed as means ± s.e.m. Statistical signifi-
cance of differences was evaluated using a paired or
unpaired two-tailed Student's t-test as appropriate, and
significance was accepted when P < 0.05.
Chemicals
Histamine dihydrochloride, indomethacin, atropine sul-
phate, Nω -nitro-L-arginine, (-)-isoprenaline hydrochlo-
ride and L-arginine hydrochloride were obtained from
Sigma Chemical Co. (St. Louis, MO, USA). Nω -hydroxy-
nor-L-arginine was kindly provided by Dr J.-L. Boucher
(Université Paris V).
Results
In guinea pig tracheal open-ring preparations, EFS
induced a frequency-dependent relaxation of histamine-
induced tone ranging from 6.6 ± 0.8% at 0.5 Hz to 74.6 ±
1.2% at 16 Hz. Incubation with the NOS inhibitor L-NNA
caused a significant inhibition of the EFS-induced relaxa-
tion at 0.5 to 8 Hz, particularly at the lower frequencies.
The effect of L-NNA ranged from 78.0 ± 10.5% inhibition
at 0.5 Hz to 26.7 ± 7.7% inhibition at 8 Hz (P < 0.01 all;
Fig. 1).
In contrast, incubation with the arginase inhibitor nor-
NOHA significantly enhanced EFS-induced relaxation by
3.3 ± 1.2-fold at 0.5 Hz to 1.2 ± 0.1-fold at 4 Hz (P < 0.05
all; Fig. 1), that is, at the frequencies most sensitive to L-
NNA. The increased relaxation in the presence of nor-
NOHA was fully reverted by L-NNA (P < 0.05 all), to the
level of control preparations in the presence of L-NNA
alone (Fig. 1).
Incubation with L-arginine caused a dose-dependent
increase of total EFS-induced relaxation, which was maxi-
mal at 5.0 mM L-arginine (data not shown). In the pres-
ence of 5.0 mM L-arginine, a significant increase in EFS-
induced relaxation was observed at all frequencies com-
pared to untreated preparations (P < 0.05 all, Fig. 2). At
the lower frequencies, this increase was similar to the
increase in EFS-induced relaxation observed after incuba-
tion with nor-NOHA (Fig. 2).
Discussion
Using perfused tracheal preparations, we have previously
demonstrated that endogenous arginase activity is
involved in the regulation of agonist-induced airway con-
striction by inhibition of NO production, presumably by
competition with cNOS for L-arginine [16]. In the present
study, we demonstrated that endogenous arginase activity
is also involved in the regulation of iNANC nerve-medi-
ated airway smooth muscle relaxation.
In line with previous observations [1], it was demon-
strated that the NOS inhibitor L-NNA inhibited EFS-
induced iNANC relaxation of guinea pig tracheal prepara-
tions. This inhibition was most pronounced at the lower
frequencies, indicating a prominent role of nNOS-derived
NO at these frequencies. By contrast, inhibition of argin-
ase activity by nor-NOHA caused a considerable (up to
3.3-fold) increase in EFS-induced relaxation at low fre-
quencies, indicating that endogenous arginase activity
restricts iNANC nerve-mediated airway smooth muscle
relaxation. The increased relaxation after arginase inhibi-
tion was completely reverted by L-NNA, clearly indicating
that arginase activity attenuates iNANC nerve-mediated
airway smooth muscle relaxation by limiting NO produc-
tion, presumably by competition with nNOS for their
common substrate, L-arginine.
The observation that exogenous L-arginine significantly
enhanced the EFS-induced airway smooth muscle relaxa-
tion confirms that L-arginine is indeed a limiting factor in
EFS-induced, NO-mediated airway smooth muscle relaxa-
tion under basal conditions. Remarkably, the effect of
nor-NOHA was similar to that observed in the presence of
the maximally effective L-arginine concentration, indicat-
ing that endogenous arginase activity is a major factor inRespiratory Research 2005, 6:23 http://respiratory-research.com/content/6/1/23
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regulating the neural NO-mediated airway smooth mus-
cle relaxation.
Recently, we discovered that increased arginase activity is
importantly involved in the pathophysiology of asthma
by contributing to the allergen-induced NO-deficiency
and subsequent airway hyperresponsiveness to metha-
choline after the early asthmatic reaction, by limiting the
availability of L-arginine for cNOS to produce bronchodi-
lating NO [22]. Arginase activity as well as expression was
also considerably increased in two mouse models of aller-
gic asthma, irrespective whether the animals were chal-
lenged with ovalbumin or with Aspergillus fumigatus [23].
Moreover, enhanced mRNA or protein expression of argi-
nase I was observed in human asthmatic lung tissue, par-
ticularly in inflammatory cells and in the airway
epithelium [23], while increased arginase activity was
measured in asthmatic serum [24]. In guinea pig tracheal
strips, it has previously been demonstrated that EFS-
induced iNANC relaxation is reduced after ovalbumin-
challenge, due to a deficiency of iNANC nerve-derived NO
[25]. Thus, it is tempting to speculate that increased
Role of NO and arginase in iNANC nerve-induced relaxation of guinea pig tracheal smooth muscle Figure 1
Role of NO and arginase in iNANC nerve-induced relaxation of guinea pig tracheal smooth muscle. Electrical 
field stimulation-induced relaxation of precontracted guinea pig tracheal open-ring preparations in the absence and presence of 
the NOS inhibitor L-NNA (100 µM), the arginase inhibitor nor-NOHA (10 µM) or a combination of both inhibitors. Results 
are means ± s.e.m. of 8 experiments. *P < 0.05 and **P < 0.01 compared to control, †P < 0.05 and ‡P < 0.01 compared to nor-
NOHA-treated.Respiratory Research 2005, 6:23 http://respiratory-research.com/content/6/1/23
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arginase activity could similarly be involved in allergen-
induced reduced iNANC activity.
A role for arginase by restricting the L-arginine availability
for nNOS in iNANC nerves has also been proposed in the
pathophysiology of erectile dysfunction [19]. In support,
increased expression and activity of arginase II contribut-
ing to reduced NO production has been demonstrated in
diabetic cavernosal tissue [26]. Neuronal arginase may
also be involved in gastrointestinal motility disorders, by
reducing nNOS-mediated iNANC relaxation in the inter-
nal anal sphincter [18].
Conclusion
This is the first demonstration that endogenous arginase
activity is functionally involved in iNANC nerve activity in
the airways, by attenuating the generation of nNOS-
derived NO. Disturbance of this novel regulation mecha-
nism of airway responsiveness might be involved in the
pathophysiology of allergic asthma.
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Role of L-arginine availability and arginase in iNANC nerve-induced relaxation of guinea pig tracheal smooth 
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